BC Innovations | Jan 8, 2019
Distillery Therapeutics


INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
BC Innovations | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferator activated receptor (PPAR) α; PPARγ coactivator 1-α (PPARGC1A, PGC-1a)

Renal INDICATION: Renal disease Studies in mice and patient samples suggest stimulating fatty acid oxidation (FAO) could help treat kidney fibrosis. In samples from patients with chronic kidney disease, mRNA levels of key FAO enzymes...
BioCentury | Jan 12, 2015
Emerging Company Profile

Targeting transcription regulators

The founders of Inventiva S.A.S. are using a platform from predecessor company Laboratoires Fournier S.A. to discover small molecules that target epigenetic enzymes, transcription factors and nuclear receptors for oncology, fibrosis and autoimmune disease. The...
BioCentury | Nov 24, 2014
Product Development


The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
BC Extra | Oct 14, 2014
Financial News

Anatara raises A$7M in Australian IPO

Anatara Lifesciences Ltd. (ASX:ANR), which is seeking partners for human development of its non-antibiotic therapy to treat and prevent diarrhea, raised A$7 million ($6.1 million) through the sale of 14 million shares at A$0.50 in...
BioCentury | Apr 14, 2014
Product Development

Family resemblance

The early Phase III data appear similar for competing anti- PCSK9 mAbs from Amgen Inc. on one end and partners Regeneron Pharmaceuticals Inc. and Sanofi on the other. But starting mid-year, additional data in the...
BioCentury | Feb 3, 2014

Lipid advice in Europe

A lack of clarity about requirements for cardiovascular safety and outcomes data in updated EMA guidance means companies developing lipid-modulating therapies will need to seek individual advice from the European regulator as early as possible...
BioCentury | Feb 3, 2014

Quick payday on single cell sale

A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in a short time. On Jan. 29, Fluidigm Corp. (NASDAQ:FLDM) announced plans to acquire fellow microfluidics company DVS...
BC Week In Review | Nov 4, 2013
Clinical News

Antara fenofibrate regulatory update

Lupin said FDA approved an sNDA for 30 and 90 mg strengths of Antara fenofibrate as an adjunct treatment for hypercholesterolemia, mixed dyslipidemia and hypertriglyceridemia in combination with diet. Lupin, which already markets 43 and...
BioCentury | Oct 28, 2013

Paying the iron price

A group of VCs and Novartis AG (NYSE:NVS; SIX:NOVN) are betting that Sideris Pharmaceuticals Inc. 's iron chelator program can better the pharma's iron overload drug Exjade deferasirox , as well as a compound from Shire...
Items per page:
1 - 10 of 149